Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytosolic carboxypeptidase 4 (AGBL1) is a metallocarboxypeptidase enzyme that catalyzes the removal of polyglutamate side chains from glutamate residues at the C-terminal tail of tubulin and other non-tubulin proteins, a process critical for regulating protein function through reversible polyglutamylation. Mutations in AGBL1 are associated with dominant late-onset Fuchs corneal dystrophy, implicating it in ocular disease pathogenesis. The enzyme participates in protein modification pathways with roles in protein–protein interactions and cellular metabolism[1][9].
Catalysis of deglutamylation; specifically, removal of polyglutamate side chains from the C-terminus of tubulin and non-tubulin proteins[1][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytosolic carboxypeptidase 4 (AGBL1).